Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.

ABSTRACT: Chemotherapy-induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care. Besides changing anticancer regimens, standard management of CIT has been limited to platelet transfusions and supportive care. Use of the thrombopoietin receptor agonist romiplostim, already approved for use in immune thrombocytopenia, has shown promising signs of efficacy in CIT. In a phase 2 prospective randomized study of solid tumor patients with platelet counts <100 × 10⁹/L for ≥4 weeks due to CIT, weekly romiplostim corrected the platelet count to >100 × 10⁹/L in 93% (14/15) of patients within 3 weeks versus 12.5% (1/8) of u

SUBMITTER: Soff GA 

PROVIDER: S-EPMC11319220 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature